Quick Answer
Akebia Therapeutics, Inc. reported Research And Development Expense of $62.36 million for the year ending 2025.
- Akebia Therapeutics, Inc. showed an increase of +65.6% in Research And Development Expense from 2024 to 2025.
- This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Akebia Therapeutics, Inc.'s Research And Development Expense has grown by 1,007.2%.
- Historical annual values: Fiscal year 2025: $62.36 million | Fiscal year 2024: $37.65 million | Fiscal year 2023: $63.08 million | Fiscal year 2022: $129.99 million | Fiscal year 2021: $147.85 million | Fiscal year 2020: $218.49 million | Fiscal year 2019: $322.97 million | Fiscal year 2018: $291.01 million | Fiscal year 2017: $230.89 million | Fiscal year 2016: $115.79 million | Fiscal year 2015: $43.02 million | Fiscal year 2014: $23.26 million | Fiscal year 2013: $8.90 million | Fiscal year 2012: $5.63 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: